BioPharma Reporter

FEBRUARY 3, 2022

Polyplus, a provider of transfection reagents, has acquired e-Zyvec, a France-based provider of DNA design and production services for tailor-made DNA vectors to expand expertise in plasmid DNA vector engineering.

DNA 52

DNA Reagent Engineer Production 52

XTalks

JANUARY 21, 2025

From non-invasive cancer diagnostics to life-saving cardiovascular implants, the latest medical devices cleared or approved by the FDA in 2024 reflect the remarkable strides in science and engineering. The Shield test provides a non-invasive approach to colorectal cancer screening by analyzing blood for key DNA changes linked to cancer.

FDA Approval 105

FDA Approval Manufacturing Development RNA 105

The Pharma Data

JANUARY 31, 2021

(NASDAQ: ILMN), the global leader in DNA sequencing and array-based technologies, and Sequoia Capital China , a leading investment firm, today announced a collaboration to catalyze the startup ecosystem in China with the launch of the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina. About Illumina.

Genome 52

Genome Genomics Life Science DNA 52

pharmaphorum

JUNE 1, 2021

Microtaggants are uniquely encoded materials that are virtually impossible to replicate or reverse engineer. Two different types of microtaggants are now available, one produced from non-biologic DNA and the other from silica: DNA microtaggants. Silica microtaggants.

Medicine 52

Medicine DNA Pharmacy Production 52

XTalks

OCTOBER 1, 2020

At Nurix, Dr. Hansen focuses on establishing the company’s DNA-encoded library technology platform for small molecule identification and leading the discovery organization. The ability to recruit the right people, especially in terms of data science and software engineers, [is there]. But in companies, you cannot do that.

Scientist 52

Scientist In-Vitro Research Life Science 52

Roots Analysis

FEBRUARY 13, 2023

It transfers genetic information form to DNA to ribosomes, a specialized structure, or organelle, which decodes genetic information into a protein. With the help of genetic engineering, synthetic mRNAs can express proteins, as they structurally resemble a natural mRNA.

Manufacturing 52

Manufacturing Drug Delivery Systems Genetic Engineering RNA 52

pharmaphorum

FEBRUARY 3, 2021

However, caveats surrounding the stochastic off-target outcomes of cleaving both strands of the DNA helix to elicit a gene modification remain a source of concern. These treatments are examples of patient-specific, engineered chimeric antigen receptor (CAR)-T cell therapies that harness the immune system to target and eliminate cancer cells.

Gene Editing 98

Gene Editing Gene DNA Engineer 98